About Shanghai Haoyuan Chemexpress Company

The company was founded in 2006 and focuses on providing professional and efficient CRO&CDMO services for the global pharmaceutical and biomedical industry. It is committed to building an integrated service platform for drug development and production in the field of research, development and production of drug molecular blocks, tool compounds, intermediates, APIs and formulations, to accelerate and empower global partners to achieve the whole process from pre-clinical to commercial production, so that drug development is more efficient and faster to benefit human health. The main business includes research and development of molecular blocks and tool compounds in the field of small molecule and new molecular drug discovery, process development and production technology improvement for small molecules and new molecular drug raw materials and intermediates, and pharmaceutical R&D, registration and production of formulations. We are committed to building an integrated service platform covering drug development and production of “starting materials - intermediates - APIs - formulations” to accelerate and empower global partners to achieve the whole process from pre-clinical to commercial production. The main products are small molecule and new molecular drug raw materials and intermediates. It has won many honorary titles such as “China's Top 50 Pharmaceutical Research and Development”, “China's Top 20 Pharmaceutical CDMO Companies”, and the “First Prize of the Science and Technology Innovation Award” of the China Association for the Promotion of Science and Technology. It has won many honorary titles such as “China's Top 50 Pharmaceutical Research and Development”, “Top 20 Chinese Pharmaceutical CDMO Companies”, “China's Top 500 New Economy Awards”, “2022 China's Top 500 New Economy Companies”, “2023 Shanghai Top 100 Hard Core Technology Enterprises”, “3rd Pharmaceutical Innovation Ji World Award Selection - Top 10 Pharmaceutical Innovation Service Agencies of the Year”, and “Influential CDMO Enterprise of the Year” in the China Biomedical Industry Chain Innovation Trend List.